Oryzon Genomics (MEX:ORYN) Tariff Resilience Score: 6/10 (As of Jun. 25, 2026)


MEX:ORYN Oryzon Genomics SA MEX:ORYN
31 GF Score
Price MXN48.59
View Full Analysis

What is Oryzon Genomics Tariff Resilience Score?

Oryzon Genomics MEX:ORYN 31 Tariff Resilience Score is 6 as of Jun. 25, 2026. GuruFocus rates MEX:ORYN with a GF Score™ of 31/100. Among 1,379 Biotechnology companies, Oryzon Genomics ranks better than 75.92% on this metric.

Oryzon Genomics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Oryzon Genomics has Oryzon Genomics, a biotech firm in Spain, faces moderate tariff exposure. While the biotech industry can be sensitive to tariffs on raw materials, the company can mitigate risks through alternative suppliers and pricing strategies. Industry-specific exemptions may apply.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Oryzon Genomics might have Average Resilient.

Oryzon Genomics  (MEX:ORYN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Oryzon Genomics Tariff Resilience Score Related Terms

MEX:ORYN vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Oryzon Genomics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oryzon Genomics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Tariff Resilience Score falls into.


MEX:ORYN
31GF Score
Oryzon Genomics SA MEX:ORYN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Oryzon Genomics (MEX:ORYN) has a Tariff Resilience Score of 6 as of Jun. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Oryzon Genomics ranks #332 out of 1379 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Oryzon Genomics' Tariff Resilience Score too high?
Oryzon Genomics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Oryzon Genomics' value of 6 is 50% above this industry median. Based on the distribution chart, Oryzon Genomics ranks #332 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #332 out of 1379 companies for Tariff Resilience Score. This places Oryzon Genomics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Oryzon Genomics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oryzon Genomics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (MEX:ORYN) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Oryzon Genomics (MEX:ORYN), the current Tariff Resilience Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for MEX:ORYN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.59
Price